Technology

Aarkstore announce a new report  “Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook” through its vast collection of market research report. Despite public policy measures to prevent cancer, such as tobacco control and vaccination against HPV, cancer is sure to remain a significant public health problem throughout the 21st century. Indeed, the global demographic shift towards an ageing population and the spread of high tech modern medicine throughout the emerging economies of Asia and (maybe later) Africa, will expand the market for cancer diagnostics globally. Major developments are likely in both the IVD market and in imaging-based modalities, like computed tomography, with the emphasis being upon the personalized medicine approach, where demand will come from physicians, patients and payors – all of whom want more effective treatments and value for money. This report analyzes the latest innovations in oncology diagnostics and identifies the most exciting new technologies and trends, ranging from body imaging and cytology to molecular diagnostics and pharmacogenomics. The report also identifies the key challenges facing innovative diagnostics companies. Key Features of this report•Analysis the latest innovations in diagnostics imaging in the oncology sector, covering Magnetic Resonance Imaging (MRI), x-ray, Computed Tomography (CT), ultrasound, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and Flow Cytometry.•Analyzes the latest innovations in molecular diagnostics and how they impact the diagnostics market. The report covers technology including fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), HPV testing, immunoassays & biomarkers, microarrays and comparative genomic hybridization (CGH).•Analyzes the latest innovations in pharmacogenomics and covers the major applications for familial cancer, breast cancer, colon cancer and lung cancer. Also, the report provides an overview of the regulatory and intellectual property environment for genetic-based tests.•Looks at the key commercial challenges for innovative diagnostics companies, including the impact of the recession, reimbursement, regulatory changes, pharmacoeconomics and the relationship between industry and academia.The report Includes in-depth case studies on the potential technologies available in core areas of un-met need such as ovarian cancer and colorectal cancer. Key benefits of this report•Understand the latest innovations in the oncology diagnostics market in the core areas – diagnostic imaging, molecular diagnostics and pharmacogenetics. This includes market information and an analysis of the scientific literature so as to identify what is really innovative.•Identify what the key areas of unmet need are in the oncology diagnostics market and understand which products have the greatest potential over the next decade.•Understand what the greatest challenges are for oncology diagnostics and what the best strategies are for coping with these obstacles. •Understand the competitive landscape and what companies are leading the way in terms of innovation, and what the latest partnerships regarding companion diagnostics.•Business Insights has identified five key areas of innovation in the diagnostics markets, use this to help guide company strategy.Key findings from this reportMolecular diagnostics and biomarkers are the key drivers of the oncology diagnostics market.Despite the deep economic recession, R&D spending has held up for oncology diagnostics companies. However, M&A activity has been impacted with the value of deals conducted in 2009 far below the peak year of 2007.Partnerships between diagnostic firms and pharmaceutical firms represents the future of the industry and the number of companion deals has been increasing in the past few years. Virtual colonoscopy – using CT scans to build a picture of the colon – is becoming an increasingly accepted alternative to invasive colonoscopy for colorectal screening in high risk groups and the general population. This presents a sizeable market opportunity. Interesting research is being conducted in both ovarian cancer and for prostate cancer, which could have wide-market implications. Specifically, companies are looking to validate new biomarkers to create more accurate tests.Key questions answered by this reportWhat is the market potential for in vitro diagnostic products?What is the market forecast for oncology diagnostics? What are the key innovations in diagnostic testing and diagnostic imaging?What are the major areas of unmet need in oncology diagnostics?What are the most promising technology areas in oncology diagnostics, and which companies are exploiting these?What will be the key trends impacting the market in the long-term?How can big pharma fully exploit the opportunities in the oncology diagnostics sector? Abbott Diagnostics Affymetrix Beckman Coulter Beckton Dickinson Bio-Rad Gen-Probe Johnson & JohnsonLuminex Nanogen Roche Diagnostics Siemens SysmexFor more information, please visit :http://www.aarkstore.com/reports/Innovations-in-Oncology-Diagnostics-Technological-advances-growth-opportunities-and-future-market-outlook-34066.htmlOr email us at press@aarkstore.com or call +919272852585 Special offer till 31th Dec 2009

Major developments are likely in both the IVD market and in imaging-based modalities, like computed tomography, with the emphasis being upon the personalized medicine approach, where demand will come from physicians, patients and payors – all of whom want more effective treatments and value for money.
This report analyzes the latest innovations in oncology diagnostics and identifies the most exciting new technologies and trends, ranging from body imaging and cytology to molecular diagnostics and pharmacogenomics. The report also identifies the key challenges facing innovative diagnostics companies.
Key Features of this report
•Analysis the latest innovations in diagnostics imaging in the oncology sector, covering Magnetic Resonance Imaging (MRI), x-ray, Computed Tomography (CT), ultrasound, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and Flow Cytometry.•Analyzes the latest innovations in molecular diagnostics and how they impact the diagnostics market. The report covers technology including fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), HPV testing, immunoassays & biomarkers, microarrays and comparative genomic hybridization (CGH).•Analyzes the latest innovations in pharmacogenomics and covers the major applications for familial cancer, breast cancer, colon cancer and lung cancer. Also, the report provides an overview of the regulatory and intellectual property environment for genetic-based tests.•Looks at the key commercial challenges for innovative diagnostics companies, including the impact of the recession, reimbursement, regulatory changes, pharmacoeconomics and the relationship between industry and academia.The report Includes in-depth case studies on the potential technologies available in core areas of un-met need such as ovarian cancer and colorectal cancer.
Key benefits of this report
•Understand the latest innovations in the oncology diagnostics market in the core areas – diagnostic imaging, molecular diagnostics and pharmacogenetics. This includes market information and an analysis of the scientific literature so as to identify what is really innovative.•Identify what the key areas of unmet need are in the oncology diagnostics market and understand which products have the greatest potential over the next decade.•Understand what the greatest challenges are for oncology diagnostics and what the best strategies are for coping with these obstacles. •Understand the competitive landscape and what companies are leading the way in terms of innovation, and what the latest partnerships regarding companion diagnostics.•Business Insights has identified five key areas of innovation in the diagnostics markets, use this to help guide company strategy.
Key findings from this report
Molecular diagnostics and biomarkers are the key drivers of the oncology diagnostics market.
Despite the deep economic recession, R&D spending has held up for oncology diagnostics companies. However, M&A activity has been impacted with the value of deals conducted in 2009 far below the peak year of 2007.
Partnerships between diagnostic firms and pharmaceutical firms represents the future of the industry and the number of companion deals has been increasing in the past few years.
Virtual colonoscopy – using CT scans to build a picture of the colon – is becoming an increasingly accepted alternative to invasive colonoscopy for colorectal screening in high risk groups and the general population. This presents a sizeable market opportunity.
Interesting research is being conducted in both ovarian cancer and for prostate cancer, which could have wide-market implications. Specifically, companies are looking to validate new biomarkers to create more accurate tests.
Key questions answered by this report
What is the market potential for in vitro diagnostic products?What is the market forecast for oncology diagnostics? What are the key innovations in diagnostic testing and diagnostic imaging?What are the major areas of unmet need in oncology diagnostics?What are the most promising technology areas in oncology diagnostics, and which companies are exploiting these?What will be the key trends impacting the market in the long-term?How can big pharma fully exploit the opportunities in the oncology diagnostics sector? 
Abbott Diagnostics Affymetrix Beckman Coulter Beckton Dickinson Bio-Rad Gen-Probe Johnson & JohnsonLuminex Nanogen Roche Diagnostics Siemens Sysmex     Table of Contents : 
Innovations in oncology diagnosticsExecutive summary 10Setting the scene 10Innovations in diagnostic imaging 11Innovations in molecular diagnostics 12Innovations in pharmacogenomics 13Challenges in the oncology diagnostics sector 14Competitive landscape 15Chapter 1 Setting the scene 18Summary 18Introduction 19Cancer facts, current and projected 19History of oncology diagnostics 23Elements of a cancer diagnosis 26Pathology 27Oncology diagnostics market 28Chapter 2 Innovations in diagnostic imaging 34Summary 34Introduction 35Body imaging 35Overview 35X-ray 38Breast cancer 38Computed tomography 40Lung cancer 40Colon cancer 40Others 42Ultrasound 44Magnetic resonance imaging 44Nuclear medicine – PET & SPECT 45Case study 47HYPERImage 47Cytology 47Overview 47Flow cytometry 48Case study 49CellSearch 49Cervical screening 50Cytogenetics 52Chapter 3 Innovations in molecular diagnostics 56Summary 56Introduction 57DNA, genes and chromosomes 59Fluorescence in situ hybridization (FISH) 59PCR and variants 60Case study 61HPV testing 61Immunoassays and biomarkers 62Case study 66Ovarian cancer 66PSA testing 68Other areas of research 70Epigenomics 71Microarrays 72Comparative genomic hybridization (CGH) 73Case study 74Almac 74DiaGenic 74Overview of clinical applications of molecular diagnostics 74BCR-ABL 74LOH 75MSI 75Chapter 4 Innovations in pharmacogenomics 78Summary 78Introduction 79Familial cancer 79Breast cancer 80Colon cancer 81Melanoma 81Case study 82IP challenge 82Response to therapy 83Cytochrome P450 variants 86HER2 overexpression 86The FDA, EMEA and PGx labeling 88Case study 89TheraScreen: KRAS 89BioTheranostics: Breast cancer 89Clarient: Breast cancer 90Marker validation for erlotinib in lung cancer 90Companion diagnostics 91Chapter 5 Challenges in the oncology diagnostics sector 94Summary 94Introduction 95Reimbursement funding 97Educated patients = educated decisions 98Regulation 99Pharmacoeconomics 101Emerging markets 104Partnerships between drug companies & academia 105Research & development 106Mergers & acquisitions 109Chapter 6 Competitive landscape 112Summary 112Introduction 113Abbot Diagnostics 113Affymetrix 114Beckman Coulter 116Becton Dickinson 117Bio-Rad Laboratories 119Gen-Probe 120Johnson & Johnson (J&J) 121Ortho Clinical Diagnostics 121Luminex 121Tm Bioscience 122Nanogen 122Roche Diagnostics 123Siemens Healthcare Diagnostics 126Sysmex 126Future perspectives in the oncology diagnostics market 127Science 127Infrastructure 128Adoption of innovation 130Companion diagnostics 131Chapter 7 Appendix 135Glossary 135Index 138List of FiguresFigure 1.1: Leading sites of new cancer US, 2009 22Figure 1.2: Leading sites of new cancer in developing countries, 2007 23Figure 1.3: Information required by oncologist pre/post diagnosis 27Figure 1.4: Oncology diagnostics forecasts ($bn), 2007-14 30Figure 2.5: Example of the use of 3D tomosynthesis imaging 39Figure 2.6: Number of CT scans in the US, 1995-2008 43Figure 2.7: Women having mammograms (%) in the US, 2004* 45Figure 2.8: Global flow cytometry market forecast ($bn), 2008-14 48Figure 3.9: IV diagnostics market forecast ($bn), 2007-2014) 58Figure 3.10: Use of biomarkers 63Figure 3.11: Obstacles to biomarker development 64Figure 3.12: US 5-year survival (%) for ovarian cancer at time of diagnosis 67Figure 4.13: Myriad: Molecular diagnostics sales ($m), 2005-09 83Figure 4.14: Number of biologics regulated by CDER that have existing PGx information 85Figure 4.15: Herceptin therapy cost ($) per patient relative to HER2 testing 87Figure 5.16: Decline in S&P global sector indices (%), 12 months to December 2008 96Figure 5.17: IV diagnostics risk-based classification 100Figure 5.18: FDA validated biomarkers by therapeutic area, September 2009 102Figure 5.19: Roche Diagnostics regional sales (CHFm), 2008 105Figure 5.20: Leading diagnostic firms increase in R&D spend (%) y-o-y, 2008 107List of TablesTable 1.1: WHO cancer mortality forecasts by region (‘000), 2008-30 21Table 1.2: In vitro diagnostics market forecast ($bn), 2008-14 29Table 2.3: Overview of imaging systems 37Table 2.4: Mortality reduction (%) attributed to FOBT screening, 1985-96 41Table 2.5: Organ radiation data from various clinical studies 44Table 3.6: Extensively investigated cancer biomarkers 65Table 3.7: Market potential for Epigenomics’ cancer specialty tests 72Table 4.8: Absent/incomplete efficacy (%) of drugs by therapeutic class 84Table 5.9: Leading M&A deals in the diagnostics industry ($m), 2009 109Table 6.10: Sales for the leading innovative oncology diagnostics companies ($m), 2006-08 113Table 6.11: Beckman Coulter R&D investment ($m), 2004-08 116Table 6.12: Bio-Rad sales ($bn) 2004-2008 119Table 6.13: Roche Diagnostics sales by division (CHFm), H109 123Table 6.14: Major recent Dx-Rx partnerships 132
  For More information please contact :

http://www.aarkstore.com/reports/Innovations-in-Oncology-Diagnostics-Technological-advances-growth-opportunities-and-future-market-outlook-34066.html

In this segment, we watch as geospatial technology transforms surveying.ATETV is a web-based video series and interactive network designed to connect students and professionals with careers in advanced technology. Our video series highlights ATE success stories from community colleges and ATE programs nationwide. For more ATETV, click here: www.atetv.org For the entire ATETV Episode 5, please click here: www.youtube.com

Aarkstore announce a new report  “Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments” through its vast collection of market research report.Leading Drug Delivery Companies and Technologies Competitive landscape, company profiles and technological developments Business Intelligence for the Pharmaceutical Industry Portfolio of healthcare management reports is designed to help you make well informed and timely business decisions. We understand the problems facing today’s pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions.

The strength of our research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors’ leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry.

Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight.

Some key findings from this report… • The oral delivery system continues to dominate the drug delivery market due to convenient usage, cost-effectiveness and low frequency of administration. Needleless injectables, PEGylation technologies and micro-electromechanical devices are among the novel technologies with the greatest growth potential. • The market for parenteral drugs and solutions sold in prefilled syringes and premixed IV systems will grow, due to the ease of administration and resistance to infections associated with these methods. The needle-free delivery sector will rise to $3bn by 2010. • Pulmonary delivery technologies are increasingly prevalent in pain management, cystic fibrosis and diabetes. Pulmonary-based delivery vehicles are currently the focus of a number of major companies including Nektar, Aradigm, 3M, and Alkermes. • Dry powder inhalers will secure the largest share of sales within the asthma market, as demand for treatments in this therapy area continues to expand. However, MDI products will experience a relatively higher rate of growth due to consistent improvements in particle size and safe propellant delivery.

Leading Drug Delivery Companies and Technologies Over the last decade, the drug delivery industry has evolved to become a key area in the development of value-added pharmaceutical products. The global market grew from $15bn to $40bn during 2000–2006 as companies increasingly turned to drug delivery technologies as a means of expanding product lifecycles, enhancing drug efficacy and maximizing revenues. Although the market is still dominated by the oral drug delivery system, a number of novel technologies are emerging across all systems of delivery. However, the pure drug delivery company model is rapidly becoming extinct as leading players attempt to consolidate their strategic opportunities by expanding their focus towards manufacturing, a trend that is expected to accelerate over the next five years.

‘Leading Drug Delivery Companies and Technologies’ is a new report examines the current and future trends that are shaping the drug delivery market and reviews the key emerging technologies across major systems of drug delivery. This report identifies the product portfolios and targeted therapeutic areas of leading drug delivery companies in addition to assessing their technology platforms to provide guidance over their applicability, regulatory implications and developmental progress. This report also evaluates the opportunities and threats facing each of the companies profiled and provides a comparative analysis of the growth strategies used to facilitate successful deals and collaborations.

Identify key trends and developments in the global drug delivery market, assess the performances and portfolios of leading drug delivery companies and benchmark their strategies with this new report…

Top reasons to order your copy today • Discover the key issues and trends in the global drug delivery market with this report’s analysis of market size and growth, the commercial value of drug delivery systems and the extended strategic focus of growing numbers of drug delivery companies. • Identify the dynamics of major drug delivery systems by evaluating the latest market developments and technological innovations in oral, pulmonary, injectable and transdermal delivery platforms. • Assess the leading players in the drug delivery market with this report’s review of the opportunities and threats, financial performances and R&D expenditures of Biovail, Elan, SkyePharma, Alkermes, Bioject, QLT, Nektar, Aradigm, Antares, Noven, Alza and 3M. • Benchmark the strategies of leading drug delivery companies by evaluating their product portfolios and pipelines, deals and alliances, targeted therapeutic areas and technology platforms

Key issues examined in this report… • Technology driving growth. Drug delivery technologies are being used to boost revenues and enhance product efficacy by developing future commercial opportunities and expanding product lifecycles. • Expanding strategic focus. A growing number of drug delivery companies are evolving into specialty pharma companies. Widening the core business to incorporate manufacturing is a strategy increasingly used to enhance revenues. • Stagnant R&D investment. The companies featured in this report recorded an average growth in R&D expenditure of just 6% during 2003–2007. This low growth in R&D spend is likely to inhibit the discovery and development of new products in the short term. • Inhaled insulin setback. The development of inhaled insulin has been the focus of many companies operating in the pulmonary drug delivery field. However, a high number late-stage terminations have raised doubts over the commercial potential of this delivery vehicle.

Your questions answered… • What are the major issues surrounding drug delivery within the global pharma industry? • What are the latest innovations and developments in different drug delivery vehicles? • What are the market dynamics for oral, injectable, pulmonary and transdermal drug delivery systems? • What are the key technologies and growth strategies of leading drug delivery companies? • What are the product portfolios, pipeline candidates, financial performances and R&D expenditures of these leading companies? • What opportunities and threats will drug delivery companies face in the future? For more information, please visit :http://www.aarkstore.com/reports/Leading-Drug-Delivery-Companies-and-Technologies-Competitive-landscape-company-profiles-and-technological-developments-14403.htmlOr email us at press@aarkstore.com or call +919272852585 Special offer till 31th Dec 2009